Reduced critical concentration might not have improved MGIT-based DST's sensitivity to rifampicin

Antimicrob Agents Chemother. 2024 May 2;68(5):e0170123. doi: 10.1128/aac.01701-23. Epub 2024 Mar 27.
No abstract available

Keywords: Mycobacterium tuberculosis; borderline rpoB mutations; rifampicin.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Humans
  • Microbial Sensitivity Tests*
  • Mycobacterium tuberculosis* / drug effects
  • Rifampin* / pharmacology

Substances

  • Rifampin
  • Antitubercular Agents